Burnett Wins $65 Mil. Allegra Job

Barr, Aaron; Lucas, Sloane
November 1998
Adweek Western Edition;11/02/98, Vol. 48 Issue 44, p54
Trade Publication
Reports on Hoechst Marion Roussel Inc.'s transfer of the advertising account for its allergy medication from Medicus Communications to Leo Burnett Co. Value of the account; Burnett's responsibilities in the deal; Role of Medicus in Hoechst's move.


Related Articles

  • Leo Burnett piles on new account wins. Wilke, Michael; Pollack, Judann // Advertising Age;11/2/1998, Vol. 69 Issue 44, p1 

    Reports that in October 1998 Leo Burnett Co. won the Hoechst Marion Roussel's $67 million Allegra allergy remedy account as well as Sara Lee Corp.'s $100 million national media buying business. How these two wins are just a part of several accounts Leo Burnett Co.'s and its subsidiaries have...

  • Hoechst in China drugs venture.  // Chemical Week;3/13/1996, Vol. 158 Issue 10, p8 

    Reports that Hoechst Marion Roussel Inc. will invest $15.3 million in a joint venture project to produce metamizol in Shanghai, China.

  • HMR expands New Jersey site.  // Chemical Week;6/12/1996, Vol. 158 Issue 23, p5 

    Reports on Hoechst Marion Roussel Inc.'s plan to expand its activities at the Somerville site in Bridgewater, New Jersey.

  • New Year resolutions. Gopal, Kevin // Pharmaceutical Executive;Jan1998, Vol. 18 Issue 1, p38 

    Reports that Hoechst Marion Roussel (HMR) Inc. will review its business operations in order to reverse its poor sales for the first nine months of 1997. Planned launching of seven products within the 200-2001 period.

  • Efficient reductions.  // Pharmaceutical Executive;Apr98, Vol. 18 Issue 4, p100 

    Reports that Hoechst Marion Roussel has announced the additional streamlining of its manufacturing operations in North America. Closure of the company's manufacturing facility in Puerto Rico and Manati, Mexico.

  • HMR goes public in defense of Cardizem CD.  // Drug Topics;3/16/98, Vol. 142 Issue 6, p7 

    States that Hoechst Marion Roussel is urging patients who use its Cardizem CD not to stop taking them in the wake of news reports on the safety of the drug. Details on the defense given to the drug by the firm; Suggestion that the study was a negative one picked up by the media.

  • Corporate independence. Gopal, Kevin // Pharmaceutical Executive;Mar1998, Vol. 18 Issue 3, p34 

    Reports on the absence of merger and acquisition plans at Hoechst Marion Roussel (HMR). HMR's plan to cut jobs worldwide; Factors that will influence the company's continuous independence.

  • Morocco.  // MEED: Middle East Economic Digest;10/10/1997, Vol. 41 Issue 41, p15 

    Looks at Hoechst Marion Roussel Inc.'s, an international merger of three large European pharmaceutical companies, investments in Morocco.

  • Hoechst Marion Roussel drugs speedup.  // Chemical Week;11/29/1995, Vol. 157 Issue 21, p7 

    Reports on Hoechst Marion Roussel Inc.'s plan to develop new drugs more quickly through its Time Optimized Product Approvals.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics